Treatment of legionellosis including a single intravenous dose of 1.5 g azithromycin: 18-year experience at a tertiary care hospital.
Administration, Intravenous
Adult
Aged
Anti-Bacterial Agents
/ therapeutic use
Austria
Azithromycin
/ therapeutic use
Female
Fluoroquinolones
/ therapeutic use
Humans
Legionella pneumophila
/ drug effects
Legionellosis
/ drug therapy
Male
Middle Aged
Retrospective Studies
Tertiary Care Centers
/ statistics & numerical data
Treatment Outcome
Antimicrobial therapy
Azithromycin
Fluoroquinolones
Legionella pneumophila
Legionnaires’ disease
Pneumonia
Journal
International journal of antimicrobial agents
ISSN: 1872-7913
Titre abrégé: Int J Antimicrob Agents
Pays: Netherlands
ID NLM: 9111860
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
03
11
2020
revised:
11
10
2021
accepted:
12
11
2021
pubmed:
22
11
2021
medline:
8
3
2022
entrez:
21
11
2021
Statut:
ppublish
Résumé
Due to recent safety concerns regarding fluoroquinolones and the potential medical and economic benefits, we investigated the efficacy of a single intravenous dose of 1.5 g azithromycin for the treatment of pulmonary legionellosis. Using a nationwide legionellosis registry for pre-selection, 74 patients admitted from 2000-2018 to a tertiary care hospital owing to pneumonia caused by Legionella pneumophila were retrospectively included in this study. Conventional treatment regimens consisting of fluoroquinolones (n = 20), macrolides (n = 30) or combinations of both (n = 24) and a single intravenous dose of azithromycin (n = 12) have been demonstrated to be equally effective. Single-dose azithromycin treatment was well tolerated and resulted in a shorter hospital stay (P = 0.0464) and shorter antibiotic treatment duration (P = 0.0004) allowing earlier discharge. A single intravenous dose of azithromycin might be a valuable treatment alternative for patients with legionellosis.
Identifiants
pubmed: 34801678
pii: S0924-8579(21)01316-9
doi: 10.1016/j.ijantimicag.2021.106481
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Fluoroquinolones
0
Azithromycin
83905-01-5
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106481Informations de copyright
Copyright © 2021 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.